Company intelligence / Profile preview

Aurion Biotech

Seattle, Washington, United States

Ownership: Private
Employees: ~67
Development stage: Phase 3

Overview

Aurion has developed AURN001, an investigational single administration allogeneic combination cell therapy product comprising human corneal endothelial cells and a ROCK inhibitor. Their first-generation product HCEC‑1 was approved and launched commercially in Japan as Vyznova in September 2024. The next-generation candidate AURN001 has completed Phase I/II CLARA trial enrollment with positive safety/tolerability results supporting advancement into Phase III. The company received FDA Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy designation for AURN001[2][3][4][6][9].

Therapeutic areas: Ophthalmology
Modalities: Allogeneic cell therapyCombination cell therapy with ROCK inhibitor
Industry: Biotech

Drug pipeline

2 assets

AURN001

1 more asset in the full pipeline.

Request access →

Partnerships

Alcon partnership providing R&D, regulatory, medical ophthalmology expertise and commercial capabilities[4]

Beyond the preview

Go deeper on Aurion Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aurion Biotech.

Explore the full profile